Clinical trial
ROMEO (Rosuvastatin in Metabolic syndrOme)
NCT00395486 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00395486 |
|---|---|
| Title | ROMEO (Rosuvastatin in Metabolic syndrOme) |
| Official title | A 6-week, Randomised, Open-label, Parallel Group, Multi-centre Study to Compare the Efficacy of Rosuvastatin 10mg With Atorvastatin 10mg in the Treatment of Metabolic Syndrome Subjects With Raised LDL-C |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Metabolic Syndrome X |
| Intervention type | Drug |
| Interventions | Rosuvastatin, Atorvastatin |
| Enrollment | 258 |
| Start date | Sep 1, 2006 |
| Primary completion | Jun 1, 2008 |
| Completion | Jun 1, 2008 |
| First posted | Nov 3, 2006 |
| Last update posted | Jul 11, 2011 |
| Countries | South Korea |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: